ENDRA Life Sciences Inc.
$6.01
▲
0.86%
2026-04-21 08:22:00
endrainc.com
NCM: NDRA
Explore ENDRA Life Sciences Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.46 M
Current Price
$6.01
52W High / Low
$11.96 / $2.9
Stock P/E
—
Book Value
$0.22
Dividend Yield
—
ROCE
-281.17%
ROE
-2.92%
Face Value
—
EPS
$-8.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
—
Beta
-0.22
Debt / Equity
21.78
Current Ratio
1.29
Quick Ratio
1.29
Forward P/E
-1.24
Price / Sales
—
Enterprise Value
$5.86 M
EV / EBITDA
-1.02
EV / Revenue
—
Rating
Strong Buy
Target Price
$27
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 2. | Precipio, Inc. | $28.15 | — | $50.21 M | — | -6.84% | -2.72% | $29.8 / $5.19 | $8.18 |
| 3. | Twist Bioscience Corporation | $61.88 | — | $3.79 B | — | -24.75% | -16.79% | $62.09 / $23.3 | $7.44 |
| 4. | Natera, Inc. | $206.53 | — | $29.47 B | — | -15.84% | -14.32% | $256.36 / $131.81 | $12.26 |
| 5. | NeoGenomics, Inc. | $8.23 | — | $1.06 B | — | -6.93% | -12.43% | $13.74 / $4.72 | $6.49 |
| 6. | GeneDx Holdings Corp. | $69.71 | — | $1.92 B | — | -3.15% | -7.6% | $170.87 / $55.17 | $10.54 |
| 7. | Personalis, Inc. | $6.34 | — | $663.37 M | — | -29.9% | -35.02% | $11.5 / $3.09 | $2.55 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.62 M | -1.37 M | -1.3 M | -1.47 M | -4.3 M | — |
| Net Profit | -3.17 M | -1.6 M | -1.23 M | -1.04 M | -4.15 M | — |
| EPS in Rs | -2.55 | -1.29 | -0.99 | -0.84 | -3.34 | -8.98 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -5.76 M | -10.82 M | -10.52 M | -13.16 M |
| Net Profit | -7.03 M | -11.51 M | -10.06 M | -13.18 M |
| EPS in Rs | -5.66 | -9.27 | -8.11 | -10.62 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.85 M | 4.45 M | 6.75 M | 9.27 M |
| Total Liabilities | 1.59 M | 1.89 M | 1.1 M | 2.07 M |
| Equity | 2.26 M | 2.56 M | 5.66 M | 7.2 M |
| Current Assets | 0.97 M | 3.43 M | 3.03 M | 5.38 M |
| Current Liabilities | 0.75 M | 0.61 M | 0.9 M | 1.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.18 M | -7.4 M | -9.55 M | -12.77 M |
| Investing CF | -3.02 M | -0.01 M | -0.02 M | -0.2 M |
| Financing CF | 5.73 M | 7.81 M | 7.52 M | 8.4 M |
| Free CF | -8.2 M | -7.42 M | -9.58 M | -12.97 M |
| Capex | -3.02 M | -0.02 M | -0.03 M | -0.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -14.39% | 23.67% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-11-07 | 1:0.0285714 |
| 2024-08-20 | 1:0.02 |
| 2022-12-09 | 1:0.05 |